ROCK2 Inhibitors
1 drugsAbout ROCK2
ROCK2, or Rho-associated coiled-coil containing protein kinase 2, is a serine/threonine kinase involved in cell motility, adhesion, and contraction by phosphorylating downstream targets.
While there is currently no genetic evidence directly linking ROCK2 to specific diseases, its role in fundamental cellular functions suggests potential therapeutic applications.
ROCK2 is targeted by one FDA-approved drug, REZUROCK, a small molecule approved in 2021. KADMON PHARMS LLC is the sole company with an approved ROCK2-targeting drug.
Top ROCK2 Drugs
KADMON PHARMS LLC is the only company with an approved drug targeting ROCK2.
Low competition suggests an opportunity for new entrants, but also highlights potential market risks.
ROCK2 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets ROCK2, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel biologics targeting ROCK2.
ROCK2 Clinical Trials 34 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on ROCK2. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 12 | 7 | 0 | 5 | 100% |
| Phase 2 | 17 | 5 | 4 | 7 | 56% |
| Phase 3 | 3 | 0 | 0 | 3 | - |
| Phase 4 | 2 | 1 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
ROCK2 Drug Approval Timeline (2021 - 2021)
The first and only drug targeting ROCK2, REZUROCK, was approved in 2021.
Recent approval suggests growing interest, but limited history indicates potential for market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 12 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on ROCK2. A trial counts if an approved drug acting on ROCK2 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.